Drug Store News

APRIL 5, 2023

The infusion clinic is referral-based and will provide treatments for rheumatology, gastroenterology, pulmonary, neurology, dermatology, oncology and other chronic conditions.

98

98

PharmExec

JANUARY 16, 2024

Company displayed findings at the 2024 Winter Clinical Dermatology Conference in Hawaii demonstrating significant improvements in atopic dermatitis and seborrheic dermatitis.

52

52

Hospital Pharmacy Europe

SEPTEMBER 28, 2023

In the TREAT trial, published in the British Journal of Dermatology , a team led by King’s College London, set out to examine the safety and efficacy of these two main first-line conventional systemic immunosuppressive therapies in children and young people with severe atopic dermatitis.

Hospitals 105

Hospitals 105

European Pharmaceutical Review

NOVEMBER 17, 2023

Almirall has licensed the rights to develop and commercialise lebrikizumab for the treatment of dermatology indications in Europe. The Phase III clinical development programme, which involved some 1,300 patients, also evaluated the safety profile of lebrikizumab. EC approval was based on three pivotal Phase III studies.

Hospitals 88

Hospitals 88

European Pharmaceutical Review

MARCH 13, 2024

In the long-term extension FRONTIER 2 study , JNJ-2113 demonstrated sustained efficacy from Week 16 to Week 52, based on data presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting. Johnson & Johnson stated that JNJ-2113 is the first targeted oral peptide designed to block the IL-23 receptor. at 16 weeks and 76.2

86

86

Hospital Pharmacy Europe

JUNE 19, 2023

Topical roflumilast is being increasingly trialled for a number of skin conditions but how effective is it, and will it take centre stage in the field of dermatology? PDE4 inhibitors have become a promising class of drugs with a potential role in a number of therapy areas such as pulmonary, dermatological and neurological diseases.

FDA 98

FDA Hospitals 98

Hospital Pharmacy Europe

FEBRUARY 27, 2024

Treatment with ritlecitinib is a one-a-day capsule that has been shown in clinical trials to reduce inflammation and hair loss at the follicle for up to two years, the final draft guidance says. The NHS approval of the treatment for people aged 12 years and older comes after an initial rejection by the committee in September.

Hospitals 52

Hospitals 52

Hospital Pharmacy Europe

APRIL 23, 2024

Bimekizumab offers a promising new therapeutic option for moderate to severe disease, supported by Phase 3 evidence that demonstrated clinically meaningful and sustained responses over 48 weeks.’ Bimekizumab treatment also resulted in clinically meaningful improvements in the ranked key secondary endpoint, HiSCR75 versus placebo at Week 16.

Medical Schools 52

Medical Schools Hospitals 52

STAT

JANUARY 17, 2024

“From dermatology and personal experience, there’s not many good treatments. Once developed, the antibody will also still need to make it through clinical trials. I’m not, not vain, but I was like I’m not paying $2,000 for a 50% chance,” Ko said. Continue to STAT+ to read the full story…

Chemotherapy 120

Chemotherapy 120

Board Vitals - Pharmacist

NOVEMBER 19, 2022

Are you ready for the American Board of Dermatology board exams? This exam consists of 300 multiple-choice questions (MCQ) that tests candidate’s knowledge of the basic science and clinical aspects of dermatology. Get started with your Dermatology board review today with 10% off the BoardVitals Dermatology question bank.

52

52

Pharmacy Times

OCTOBER 27, 2022

Strengthening partnerships with healthcare professionals and driving awareness on the clinical benefits of dermatological skincare is the key to success in the public health space.

65

65

Pharmafile

MARCH 31, 2023

ALM) , a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. March 31, 2023 – Almirall, S.A. read more

52

52

pharmaphorum

NOVEMBER 11, 2021

KNUTSFORD, United Kingdom — Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology. Kenneth B Gordon, MD, Professor and Chair of Dermatology at the Medical College of Wisconsin. November 10, 2021, UK. Visit us at ? About FIDE.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Patient Care 98

Pharmafile

MARCH 30, 2023

Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development. Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development. read more

52

52

European Pharmaceutical Review

APRIL 27, 2023

Clinical trial data for Cosentyx The study data is based on two trials in the largest Phase III programme in HS: SUNSHINE and SUNRISE. The full results were recently published in The Lancet. “If

Medical Schools 84

Medical Schools FDA 84

European Pharmaceutical Review

APRIL 26, 2024

AbbVie stated that the observed safety profile for upadacitinib in the Phase IIIb/IV trial was consistent with those in previous upadacitinib atopic dermatitis clinical studies. Patients treated with upadacitinib: Achieved EASI 90 at Week 16 (40.8 percent vs 22.5 percent) Achieved a WP-NRS of 0/1 at Week 16 (30.2 percent vs 15.5

Labelling 58

Labelling 58

The Checkup by Singlecare

FEBRUARY 27, 2024

Colloidal oatmeal treatments have been around since 1945 for dermatological use and are widely available today in bath soaps, shampoos, face masks, shaving gels, and moisturizing creams. For centuries, oatmeal has been used as a treatment for skin irritations like rashes, burns, insect bites, eczema, and psoriasis.

Compounding 83

Compounding 83

The Checkup by Singlecare

FEBRUARY 8, 2024

An elimination diet can sometimes help narrow down food triggers, but eliminating foods can be difficult, doesn’t always work, and can cause more harm than good, notes the American Academy of Dermatology.

Immunization 105

Immunization Compounding 105

European Pharmaceutical Review

APRIL 26, 2024

It is approved for autoimmune disorders within disease areas such as gastroenterology and dermatology. Pyzchiva was developed and registered by Samsung Bioepis to match the reference medicine.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies FDA 52

European Pharmaceutical Review

JANUARY 11, 2024

billion, so biosimilar competition could significantly expand patient access to this biologic therapy within the fields of gastroenterology, dermatology, and rheumatology, according to STADA and Alvotech. The EU ustekinumab market is worth €2.5 In this region, STADA already has six biosimilars approved in this market.

Immunization 105

Immunization 105

Pharmaceutical Technology

JANUARY 19, 2023

Concert’s patent portfolio includes oral Janus kinases JAK1/2 inhibitor, deuruxolitinib, to treat Alopecia Areata, an autoimmune dermatological disease. Deuruxolitinib’s safety and efficacy was assessed in moderate to severe Alopecia Areata adult patients in the THRIVE-AA Phase III clinical programme.

Labelling 59

Labelling FDA 59

Hospital Pharmacy Europe

JUNE 22, 2023

Moreover, these decisions are further hampered by the fact that pregnant women are invariably excluded from clinical trials using biologics.

Hospitals 94

Hospitals 94

STAT

DECEMBER 2, 2022

And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies. And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies.

88

88

Pharmaceutical Technology

MAY 19, 2023

Clinical response was observed after just two weeks in some cases. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology. Patients showed a visible reduction of damage to the intestinal lining after 12 weeks of 45mg Rinvoq treatment.

Mayo Clinic 105

Mayo Clinic Dosage FDA Immunization 105

European Pharmaceutical Review

SEPTEMBER 11, 2023

Clinical evidence for SB17 Phase I results presented by Samsung Bioepis at the American Academy of Dermatology (AAD) Annual Meeting, in March 2023 demonstrated that SB17 matches the pharmacokinetic (PK) bioequivalence, safety, tolerability, and immunogenicity of ustekinumab.

81

81

pharmaphorum

JULY 5, 2022

With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. Instead, atopic dermatitis clinical trial organisers often simply only reach out to a limited patient population and fail to reach the complete, diverse, patient population of atopic dermatitis.

Communication 117

Communication 117

Hospital Pharmacy Europe

OCTOBER 12, 2023

The psychological burden and subsequent impact on quality of life of skin diseases such as acne, hidradenitis suppurativa and urticaria has been revealed in a large pan-European study published in the Journal of the European Academy of Dermatology and Venereology (EADV).

Hospitals 52

Hospitals 52

Pharma Mirror

SEPTEMBER 16, 2022

Barcelon, a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE, an interventional phase IV clinical study, which resembled real-life clinical practice. In this study, Ilumetri®?

52

52

pharmaphorum

AUGUST 17, 2022

At Fishawack Health (FH), we are committed to investing in the field of dermatology. In November 2022, we welcomed FIDE , an independent network of expert partners in dermatology, to inform industry specialists as to the potential impact of the latest data and how it may affect their strategic decision-making.

52

52

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. However, side effects do happen.

Medical Schools 100

Medical Schools Hospitals Dosage Labelling 100

European Pharmaceutical Review

DECEMBER 15, 2022

The primary endpoint in both trials evaluated the proportion of patients with clinically meaningful improvement in itch from baseline (measured by a ≥4-point reduction in Worst-Itch Numeric Rating Scale [WI-NRS] on a 0-10 scale) at 24 and 12 weeks, respectively. Phase III trial data that formed the basis of the EC’s approval.

Hospitals 88

Hospitals 88

European Pharmaceutical Review

MAY 24, 2023

Results from the clinical trials for the redosable gene therapy The redosable gene therapy is the first and only medicine approved by the FDA for the treatment of DEB, both recessive and dominant” The FDA approval of VYJUVEK is based on two clinical studies: the GEM-1/2 trial and GEM-3 trial.

FDA 101

FDA 101

European Pharmaceutical Review

JANUARY 24, 2024

It is the first prospective, large-scale, randomised-controlled clinical trial evaluating people of colour across all skin tones with moderate to severe plaque PsO and scalp PsO to objectively measure clearance and other treatment outcomes with Tremfya.

84

84

Hospital Pharmacy Europe

JUNE 28, 2023

Adalimumab dosing is not weight-based and in two phase 3 trials, just over half of the patients assigned to adalimumab 40 mg/week (ADA40) achieved a clinical response. Patients experienced a greater improvement in the HS-Physician Global Assessment with ADA80 compared to ADA40 (p = 0.01).

Documentation 52

Documentation Hospitals 52

Hospital Pharmacy Europe

OCTOBER 30, 2023

Commenting on the development, Dr John Ingram, clinical reader and consultant dermatologist at Cardiff University, said: ‘HS is an undertreated disease that causes substantial physical and emotional distress to those who live with it. Approximately 50% of patients randomised to secukinumab had a reduction in HS-related pain at Week 52.

Hospitals 52

Hospitals 52

Pharmaceutical Technology

JULY 12, 2022

A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses. The NDS submission by Arcutis is based on positive findings from the company’s pivotal Phase III programme and two long-term open-label clinical trials. Health Canada has provided a target action date of 30 April next year.

Labelling 64

Labelling Immunization 64

Pharmaceutical Technology

APRIL 17, 2023

The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. The company will help in managing the clinical trials of the products once the regulators provide approvals for the proposed research and development programmes.

Immunization 52

Immunization Pharmaceutical Companies Pharmaceutical Companies FDA 52